m+Medelevator.RU
← Поиск публикаций
Cancer research · 2025

Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination-Deficient Breast Cancer.

СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Pedretti Flaminia, Abdalfttah Mohmed, Pellegrino Benedetta, Mateo Francesca, Martínez-Sanz Paula, Herencia-Ropero Andrea, Òdena Andreu, Clavell-Revelles Pau, Casali Giorgia, Domènech Heura, Monserrat Laia, Papić Dražen, Mas Malavila Alba, Pascual-Reguant Anna, Eixarch Herena, Guzmán Marta, Rodríguez Olga, Grueso Judit, Simonetti Sara, Fasani Roberta, Nuciforo Paolo, Espejo Carmen, Florian Stefan, Pujana Miguel Ángel, Nonell Lara, Seoane Joan, Valge-Archer Viia, O'Connor Mark J, Nieto Juan C, Heyn Holger, Balmaña Judith, Llop-Guevara Alba, Serra Violeta

Аннотация

Homologous recombination deficiency (HRD) contributes to genomic instability and leads to sensitivity to PARP inhibitors (PARPi). HRD also activates the cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING)-interferon pathway, highlighting the need to understand the impact of cGAS-STING-IFN signaling on PARPi efficacy. In this study, we analyzed a cohort of 35 breast cancer patient-derived xenografts and mouse-derived allografts. PARPi sensitivity correlated with HRD, increased genomic instability, and activation of the cGAS-STING-IFN signaling pathway. Single-cell analyses showed that IFN signaling and IFN-based immune interactions were suppressed in preclinical models with acquired resistance to PARPi, lacking concomitant clonal expansion of functional CD8+ T cells. However, the combination of a PARPi and a novel STING agonist (STINGa) increased immune infiltration and resulted in superior antitumor activity in these tumors. Notably, the efficacy of PARPi monotherapy and the combination treatment with a STINGa was dependent on natural killer (NK) cells. In agreement, patients with breast cancer with BRCA1/BRCA2 mutations and good responses to PARPi showed higher abundancy of CD56+ NK cells in the tumor microenvironment and treatment-engaged CD56bright NK cells in the peripheral immune compartment, compared with those with poor responses. Therefore, these findings propose the combination of PARPis and a STINGa as a potential novel strategy to enhance the therapeutic response in patients with acquired PARPi resistance and highlight a pivotal role of NK cells in the PARPi antitumor activity. Significance: PARP inhibitor sensitivity is associated with cGAS-STING-IFN signaling, which can be harnessed by combining PARP inhibitors with STING agonists to overcome acquired resistance and requires NK cells to mediate antitumor immunity. See related commentary by Gohari et al., p. 1747.

Предметные рубрики MeSH

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты